Phase 2 Data Presentations at The Liver Meeting ® Detail SVR12 Rates from Two Studies as Well as SVR8 Rates in Patients for Whom Direct-Acting Antiviral Treatment Previously Failed

http://hepatitisc.hcvadvocate.org/2016/11/merck-announces-findings-investigational-triple-combination-chronic-hepatitis-c-therapy-showing-high-rates-sustained-virologic-response-people-genotypes-1-2-3-infection.html